Ricevi le ultime notizie sulle azioni Evotec con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di EVO

Ultime notizie per

Evotec

Eaton Vance Ohio Municipal Income Trust Shares of Beneficial Interest

Eaton Vance Ohio Municip

Eaton Vance Ohio

Eaton Vance Ohio Municipal Income Trust

AMEX

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec SE

Evoke Pharma Inc

EVO TRANSPORTATION by EVO Transportation & Energy Services, Inc.

EVO Transportation & Energy Services Inc

EVOLVE ETHER ETF UNHDG UT by EVOLVE ETHER ETF

EVOAIR HOLDINGS INC by EvoAir Holdings Inc.

EvoAir Holdings Inc

EvoAir Holdings Inc Ordinary Shares

SYMBOLIC LOGIC INC by Symbolic Logic Inc.

Symbolic Logic Inc

Envoy Technologies Inc

Earnings

Press Releases

Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025

Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment

News

Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments

Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury

Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance

Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix

Contracts

Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site

Evotec SE to announce first half-year results 2025 on 13 August 2025

Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution

SDZNY

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

CryoPort

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings

Fortrea Holdings

Standard BioTools

Mesa Laboratories

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

Niagen Bioscience

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences

Personalis

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Repligen

Sotera Health

Stevanato Group

Bio-Techne

10x Genomics

HC Wainwright & Co.

Jefferies

Morgan Stanley

B of A Securities

Comments

Evotec Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO